Rakuten Securities Inc. Boosts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Rakuten Securities Inc. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 248.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,160 shares of the company’s stock after buying an additional 18,661 shares during the quarter. Rakuten Securities Inc.’s holdings in Moderna were worth $742,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in MRNA. Empowered Funds LLC boosted its stake in Moderna by 11.2% in the 4th quarter. Empowered Funds LLC now owns 5,781 shares of the company’s stock worth $240,000 after purchasing an additional 582 shares in the last quarter. Asset Management One Co. Ltd. increased its stake in Moderna by 1.1% during the 4th quarter. Asset Management One Co. Ltd. now owns 123,051 shares of the company’s stock valued at $4,938,000 after purchasing an additional 1,381 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in Moderna by 38.0% in the fourth quarter. V Square Quantitative Management LLC now owns 7,797 shares of the company’s stock worth $324,000 after buying an additional 2,148 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Moderna by 140.1% in the fourth quarter. Blue Trust Inc. now owns 1,755 shares of the company’s stock worth $73,000 after buying an additional 1,024 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on MRNA. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, June 2nd. UBS Group lowered their price target on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Royal Bank of Canada dropped their price objective on Moderna from $32.00 to $28.00 and set a “sector perform” rating on the stock in a research report on Friday, May 2nd. Barclays decreased their target price on Moderna from $45.00 to $40.00 and set an “equal weight” rating for the company in a research report on Friday, May 2nd. Finally, Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price target on the stock. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus target price of $46.61.

Moderna Price Performance

NASDAQ:MRNA opened at $26.00 on Tuesday. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of -2.80 and a beta of 1.86. Moderna, Inc. has a one year low of $23.15 and a one year high of $139.92. The business has a fifty day moving average price of $26.32 and a 200-day moving average price of $32.79.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna’s revenue for the quarter was down 35.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.07) earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.